



This Teachers' Day,  
**deepen the bond of knowledge** with your mentor!

Business News > Industry > Healthcare/Biotech > Pharmaceuticals > Government need not consult statutory board to ban combo drugs: Supreme Court

Search for News, Stock Quotes & NAV's

03:29 PM | 04 SEP **LIVE**  
**MARKET STATS**

सैंसेक्स  
**38,187** ▼ -124.79

निफ्टी 50  
**11,522** ▼ -60.15

सोना (एमसीएक्स) (₹/10 ...  
**30,251.00** ▼ -76.00

यूएसडी/भारतीय ...  
**71.48** ▲ 0.26

पोर्टफोलियो  
बनाएं

ई-टी मार्केट एप  
डाउनलोड करें

CHOOSE  
LANGUAGE  
HIN

## Government need not consult statutory board to ban combo drugs: Supreme Court

By [Samanwaya Rautray](#), [Prabha Raghavan](#), ET Bureau | Updated: Nov 16, 2017, 04:38 PM IST

0  
Comments



NEW DELHI: The [Supreme Court](#) on Wednesday said the central government need not consult the statutory board on drugs before banning any fixed-drug combinations, an observation that goes against a major legal plank of companies battling against a ban on 344 such products.

Fixed-dose combinations (FDCs) are cocktail drugs of two or more therapeutic ingredients packed in a single dose.

A central government notification banning the 344 fixed-dose combinations in 2016 was set aside by the Delhi High Court in December. The government had banned these combinations in public interest, claiming they were unsafe and "irrational".

The ban had hit several popular brands like Corex, Saridon, D'Cold Total and Vicks Action 500 Extra, prompting pharma companies to submit over 500 petitions at around 10 high courts, with Delhi receiving a sizeable chunk.

The government challenged these in the top court on the ground that the ban was necessary in public interest, prompting the top court to stay the order.

Pharma companies such as [Glenmark](#) (NSE:-0.60%), [Pfizer](#) (NSE:-1.79%) and Procter & Gamble had contended that the principle of natural justice required some kind of hearing from stakeholders before the government can take a call on a technical subject like this one.



### SPOTLIGHT

Sponsored

Equity»Multi Cap



**Mirae Asset India Equity Fund Direct-Growth**

★★★★★ Figures in %

1M	3M	6M	1Yr	3Yrs
3.08	8.69	8.88	13.58	18.06

**BUY NOW**

For regulatory disclaimers, [click here](#).



**Are you an Advertising & Marketing Agency?**  
Get Your Listing on Economic Times

CREATE FREE LISTING

Most Read | Most Shared | Most Commented

The mother of all banks is coming today: 10 things

1 Government need not consult statutory board to ban combo drugs: Supreme Court

2 India's oxytocin ban delayed by a month as Delhi HC hears cases against it

3 Gland Pharma seeks pitches from investment bankers to go public

4 Domestic pharmaceutical players eye Bharat Serums acquisition

5 Gl...  
ge  
inh

Before prohibiting fixed-dose combination drugs, the government must consult the statutory bodies provided for in the Drugs and Cosmetics Act, the companies had argued before a bench of Justices RF Nariman and Sanjay Kishan Kaul.

"Otherwise the power would be unfettered, unlimited," senior advocate Abhishek Manu Singhvi had said. "This cannot be done without consulting the stakeholders. Public safety, public risk can only be assessed on the basis of expert inputs."

In the absence of an emergency, such a consultation should be made mandatory, he had argued.

Justice Nariman, however, said such consultations were not specified in Section 26A of the act, which defines the power of the Central government to regulate the manufacture and sale of drugs and cosmetics in public interest.

"If we hold otherwise, we will neither be reading the law up or down but reading in, which is legislating," Nariman said. Justice Kaul also said the arguments would have been appealing had the subject matter been anything but drugs.

The court said it was with the government on this legal point. The companies will now likely argue the other legal points against the ban at the next hearing, scheduled for Dec 6.

"Arguments on December 6 will look at how many FDCs can be excluded from the ban and how many we are not able to justify entirely," a lawyer involved in the case told ET, speaking on the condition of anonymity.

The industry is positive about the court's decision to allow further arguments in this case.

"The judge is open to hearing a little bit from our side as well, which is positive," said RK Sanghavi of pharmaceutical lobby group Indian Drug Manufacturers Association.

The association on Wednesday submitted a list of around 175 FDCs out of the original list of 344 that it had determined were not only safe for consumption but needed for specific patients, he said.

This list excluded the FDCs approved before 1988 and those already approved by the Drug Controller General of India, he added.

"The judgment will definitely have an impact depending on how much commercials are at stake and more importantly on the patients' dependency on such FDCs, especially in cases of chronic diseases," said Ashish Prasad, partner at Economic Laws Practice.

Save

0

Comments

**Are you a Business Owner? Get Your Free Business Listing on [Economic Times](#).**

[Register Now](#)

THE ECONOMIC TIMES  
**ETRISE**  
Connect with us

section

[Jio claims good response to broadband offer](#)

[At first town hall, 18,000 Vodafone Idea employees told to use size, become strongest](#)

[Train reservation charts on coaches become a thing of the past](#)

[More »](#)

## Industry Top Trending Terms

[Bad Loan](#) [Petrol price hike](#) [Bharti Airtel](#)

[Construction Ban](#) [CAPA India](#) [100 New Airports](#)

[Airlines Industry Loss](#) [Raghuram Rajan](#) [Plastic in Salt](#)

[Mahindra Marazzo Launched](#)

[Mahindra Marazzo launched video](#)



**ET** ECONOMICTIMES.COM

**Stay ahead in your business. With business news that matters.**

**Subscribe to ET's Newsletter**

**SUBSCRIBE NOW**



## Why Ford India needs a tie-up with M&M

Why Indians are swiping left on desi dating apps

ET

The J&J hip-implant mess needs a closer look

ET

[GO TO ET PRIME →](#)

**Read more on**

[Combo Drugs](#)

[Supreme Court](#)

[Pfizer](#)

[Procter & Gamble](#)

[Glenmark](#)

## Also Read

[Health ministry likely to ban over 300 combo drugs](#)

[Government buys time to amend its petition on combo drugs ban](#)

1 Government need not consult statutory board to ban combo drugs: Supreme Court

2 India's oxytocin ban delayed by a month as Delhi HC hears cases against it

3 Gland Pharma seeks pitches from investment bankers to go public

4 Domestic pharmaceutical players eye Bharat Serums acquisition


5 Gl...  
ge  
inh

Comments (0)

Add Your Comments

From Around The Web

Sponsored by



Get cash in hand weekly in India with this investment tactic

FGmarkets




Reach to 200 Million+ Readers on Economic Times

Economic Times



Own a Godrej home with EMIs\* less than your flight tickets

Godrej Oasis



प्राकृतिक रूप से बालों को उगाने के लिए 1 आसान तरीका

Regrow

More from The Economic Times



Why headline GDP numbers alone don't matter



Sale of religious books, DVDs to attract GST: AAR



A serious oil shock is in the making for India



10 most promising chefs who lead by their originality

NEXT STORY

India's oxytocin ban delayed by a month as Delhi HC hears cases against it

By [Prabha Raghavan](#), ET Bureau | Updated: Sep 02, 2018, 06.34 AM IST

0

Comments



The impending ban had sent hospitals into a panic-buying mode.

NEW DELHI: The Delhi High Court has suspended the health ministry's restrictions on private companies making and selling lifesaving drug **oxytocin** for a month while it hears petitions opposing the move. The court will hear the case next on September 12, it said on Friday.

"This is an interim move for the court to provide enough room to hearing all the arguments in this case," a lawyer present in court said on condition of anonymity.

Oxytocin is a hormone drug used to induce labour in pregnant women and prevent post-partum bleeding. The curbs were aimed at preventing illegal supply and misuse of the drug in cattle.

Are you an Advertising & Marketing Agency?  
Get Your Listing on Economic Times

CREATE FREE LISTING

Most Read   Most Shared   Most Commented

[The mother of all banks is coming today: 10 things to know](#)

[Modi's Ayushman Bharat is born through caesarean section](#)

[Jio claims good response to broadband offer](#)

[At first town hall, 18,000 Vodafone Idea employees told to use size, become strongest](#)

[Train reservation charts on coaches become a thing of the past](#)

[More »](#)

Industry Top Trending Terms

[Bad Loan](#)   [Petrol price hike](#)   [Bharti Airtel](#)  
[Construction Ban](#)   [CAPA India](#)   [100 New Airports](#)

1	Government need not consult statutory board to ban combo drugs: Supreme Court	2	India's oxytocin ban delayed by a month as Delhi HC hears cases against it	3	Gland Pharma seeks pitches from investment bankers to go public	4	Domestic pharmaceutical players eye Bharat Serums acquisition	5	Gle ge inh
---	---	---	--	---	---	---	---	---	------------

According to the court order, statutory bodies Drugs Technical Advisory Board and Drugs Consultative Committee raised concerns that emphasise that prohibition or restricted sale of oxytocin "would not be in order."

As many as 116 inspections to track illegal sales of oxytocin have resulted in prosecution in 12 instances in the past four years and the figures suggest that only two out of 112 licensed manufacturers have had their permits suspended, according to the order. The details of seizures conducted suggest that abuse of the drug is widespread only in regions including Bihar and West Bengal, Justices S Ravindra Bhat and AK Chawla said in the order.

"The materials disclosed to the court also show that when the discussion to restrict the domestic sale of oxytocin was taken in February 2018, KAPL, as a matter of fact, was not even licensed to manufacture the drug," they said, adding that the company was issued a licence in April 2018.

Mylan is one of the companies that has opposed the ministry's plan in court. Pfizer has stopped manufacturing the drug and planned to exhaust its inventory of the product within two months, ET reported on July 26.

ET had also reported then that the impending move had sent hospitals into a panic-buying mode. The size of the oxytocin market was about Rs 50 crore in the 12 months ended July 2018, with Pfizer capturing an over 40% share, according to pharmaceutical market research firm AIOCD PharmaTrac.

Patient activist group All India Drug Action Network has also filed a petition, which is being heard along with the pleas of Mylan subsidiary BGP Products Operations GmbH and Neon Laboratories.

"KAPL's ability to single-handedly produce an emergency drug for the entire country and ensure the supply all over India while maintaining a cold chain... is untried and untested," AIDAN said in its petition, a copy of which ET has reviewed. "A slight disruption or problem in functioning of the supply chain would mean unnecessary maternal deaths."

Oxytocin is considered a lifesaving drug and is included in the National List of Essential Medicines of 2011 and 2015 as well as the WHO Model List of Essential Medicines.

About four women die every hour in India from complications developed during childbirth, with heavy blood loss from haemorrhaging being "a major factor," AIDAN said in the petition, citing data from the Registrar General of India.

ET's queries to Mylan, Neon Laboratories and AIDAN remained unanswered by press time on Friday.



## Why Ford India needs a tie-up with M&M

Why Indians are swiping left on desi dating apps

ET

The J&J hip-implant mess needs a closer look

ET

GO TO ET PRIME →

0

Comments

Are you a Business Owner? Get Your Free Business Listing on **Economic Times**.

Register Now

THE ECONOMIC TIMES  
**ETRISE**  
Connect with us

Read more on

Oxytocin

Health Ministry

Oxytocin Ban

Oxytocin Price

Delhi Hc

1

Government need not consult statutory board to ban combo drugs: Supreme Court

2

India's oxytocin ban delayed by a month as Delhi HC hears cases against it

3

Gland Pharma seeks pitches from investment bankers to go public

4

Domestic pharmaceutical players eye Bharat Serums acquisition

5

Gl  
ge  
inh

Enforcement agency's role is important to ensure there is no misuse of oxytocin: KAPL

Oxytocin ban: Drug makers report panic buying by hospitals

Oxytocin formulations ban to come into effect from July 1

From Around The Web

Sponsored by



The College Board India  
Global Alliance  
The College Board



Amazon Business-GST  
Invoice & Bulk Discounts  
Amazon Business



क्या आप गंजे हो रहे हैं? यह  
आयुर्वेदिक नुस्खा आपकी मदद  
करेगा  
Nutralyfe



Respect, integrity &  
compassion define our core  
values  
The HDFC School

More from The Economic Times



Fastest-growing India sits on  
a wobbly throne



Traffic jams in Delhi may  
become a thing of past



Don't intend to use 'khadi'  
term for our products:  
Fabindia




Housing heads for worst  
slowdown in years


Get a Quote

Get Quote

- Browse Companies
- A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | 1 2 3 4 5 6 7 8 9
- Browse Mutual Funds
- A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

 **ECONOMICTIMES.COM**

Stay ahead in your business.  
With business news that matters.



Subscribe to ET's Newsletter

SUBSCRIBE NOW

Powered by	Live Market	Industry	About Us
	News	Newsletters	Create Your Own Ad
	Portfolio	Commodities	Advertise with Us
	Mobile	Speed	Terms of Use & Grievance Redressal
	Live TV	Blogs	Privacy policy
	Biz Listings	RSS	

FOLLOW US

- Download it from  
APP STORE
- Download it from  
GOOGLE PLAY
- Download it from  
Windows Store

Other Times Group news sites

इकनॉमिक टाइम्स| ેኦनोमिड टाइम्स | Pune Mirror | Bangalore Mirror | Ahmedabad Mirror | ItsMyAscent | Education Times | Brand Capital | Mumbai Mirror | Times Now |

Indiatimes | नवभारत टाइम्स | महाराष्ट्र टाइम्स | ವಿಜಯ ಕರ್ನಾಟಕ | Go Green | AdAge India | Eisamay | IGN India | NavGujarat Samay | Times of India | Samayam Tamil | Samayam Telugu | Miss Kyra | Bombay Times | Filmipop | Games App

Living and Entertainment

Timescity| iDiva | Entertainment | Zoom | Healthmeup | Luxpresso | Gadget Reviews | Titanium & Platinum Credit Card | Online Songs | MensXP | Hotels | Travel Destinations | Cricbuzz | Recipes | Gaana | Happytrips | Getsmartapp

Interest Network

itimes

Hot on the Web

Share Market | GST | Income Tax Slabs | Aadhaar Card | IFSC Code | Mutual Funds | Top ELSS Funds to Invest | How to save Income Tax | Sensex Today | Nifty Bank | How to earn money | Income Tax Calculator

Services

Book print ads| Online shopping | Matrimonial | Astrology | Jobs | Tech Community | Property | Buy car | Bikes in India | Free Classifieds | Send money to India | Used Cars | Restaurants in Delhi | Remit to India | Buy Mobiles | Listen Songs | News | TimesMobile | Real Estate Developers | Restaurant Deals in Delhi | Car Insurance | Gadgets Now | Free Business Listings | CouponDunia | Remit2India | Techradar | AliveAR | Getsmartapp App | ETMoney Finance App | Feedback | Auto

1	Government need not consult statutory board to ban combo drugs: Supreme Court	2	India's oxytocin ban delayed by a month as Delhi HC hears cases against it	3	Gland Pharma seeks pitches from investment bankers to go public	4	Domestic pharmaceutical players eye Bharat Serums acquisition	5	Gle ge inh
---	---	---	--	---	---	---	---	---	------------

- [Home Loan Calculator](#)  
[Chanda Kochhar](#)  
[Income Tax](#)  
[Jio broadband offer](#)  
[Indian Railways](#)
- [How to file ITR](#)  
[Education Loan Calculator](#)  
[Vedanta Resource](#)  
[IFSC Code](#)  
[Petrol Price Hike](#)

Copyright © 2018 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: [Times Syndication Service](#)